Marvel Biosciences Corp. MRVL.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada
Marvel Biosciences Corp. is a pre-clinical stage pharmaceutical development company based in Calgary, Canada, that employs a drug redevelopment approach to identify and evaluate therapeutic compounds for new disease indications. The company's lead compound, MB-204, is a novel fluorinated derivative of istradefylline — an adenosine A2a receptor antagonist — being investigated for the treatment of Alzheimer's disease, autism spectrum disorder, depression, and anxiety.
Key ratios
ReturnOnAssets TTM -2.9
ReturnOnAssets 2025 -2.28
ReturnOnAssets 2024 -1.32
ReturnOnAssets 2023 -1.73
Recent news
Marvel Biosciences Announces Private Placement for up to $3.0 Million
2026-07-16 · Newsfile
Marvel Biosciences Announces Grant of Deferred Share Units
2026-05-20 · Newsfile Corp.
Marvel Biosciences Announces Closing of Convertible Debenture Offering
2026-04-17 · Newsfile Corp.